Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
NCT06479954 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2025-10-02
Summary
To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.
Conditions
- Relapsed and Refractory Multiple Myeloma (RRMM)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-30
- Primary Completion
- 2027-02-25
- Completion
- 2027-02-25
Countries
- Japan
Study Locations
More Related Trials
-
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06421675 ·Status: RECRUITING ·Phase: PHASE2
-
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
NCT05647512 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
NCT05228470 ·Status: COMPLETED ·Phase: PHASE2
-
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
NCT04798586 ·Status: COMPLETED ·Phase: PHASE1
-
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT03411031 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01632150 ·Status: COMPLETED ·Phase: PHASE2
-
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566 ·Status: TERMINATED ·Phase: PHASE2
-
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
NCT03000634 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
NCT02115035 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT04649359 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
NCT05289492 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06232707 ·Status: WITHDRAWN ·Phase: PHASE3
-
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
NCT04941937 ·Status: RECRUITING ·Phase: PHASE2
-
ELISA in Relapsed/Refractory MM
NCT06832865 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584 ·Status: RECRUITING
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2